To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults

Subjects will receive 13 doses of the UB-421 by intravenous infusion at 25 mg/kg bi-weekly (Cohort 2, 26 weeks).

Subjects will receive current standard HAART treatment as the active control group.